Beigene ltd
BGNE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
BGNE 近期報酬表現
1.68%
Beigene ltd
2.06%
同產業平均
-0.34%
S&P500
與 BGNE 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
HCM | Hutchmed (china) ltd | 2 分 | 5 分 | 2 分 | 1 分 | 1 分 | |
ZLAB | Zai lab ltd | 3 分 | 2 分 | 3 分 | 3 分 | 1 分 | |
VCYT | Veracyte inc | 3 分 | 1 分 | 2 分 | 2 分 | 1 分 | |
ADPT | Adaptive biotechnologies corp | 4 分 | 1 分 | 3 分 | 3 分 | 1 分 | |
QURE | Uniqure nv | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 |
- HCM Hutchmed (china) ltd價值 2 分趨勢 5 分波段 2 分籌碼 1 分股利 1 分查看更多
BGNE 公司資訊
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.